MD, University of Patras Medical School, Greece
Neurology residency, McGaw Medical Center of Northwestern University
Movement disorders fellowship, Rush University Medical Center
Kompoliti is active in clinical research investigating novel medications and interventions to treat Parkinson's disease, Tourette syndrome, functional movement disorders, tremor and dystonia
Aikaterini (Katie) Kompoliti, MD, was born in Greece and completed her early education there, including medical school. After graduating from the University of Patras Medical School, Greece, she pursued her interest in neuroscience by completing a residency in neurology at Northwestern University, Chicago. Upon completion of her residency she held a fellowship in movement disorders at Rush University Medical Center, Chicago. Following her fellowship, she became a faculty member in movement disorders in the Department of Neurological Sciences at Rush University Medical Center where she is currently professor of neurology. She is the author and coauthor of numerous publications. Her clinical interests as a principal investigator have focused on several therapeutic areas including studies to evaluate the safety and efficacy of new compounds to treat Parkinson’s disease, Tourette syndrome, functional movement disorders and dystonia. Furthermore, she is the educational director of the section of movement disorders and the director of the movement disorders fellowship at Rush University Medical Center.
Member, National Medical Advisory Board for the Tourette Association of America, 2001- 2014
Travel fellowship, 121st Annual Meeting of the American Neurological Association, 1996
TV50717-CNS-30060
Nuvelution TS Pharma
Principal Investigator
A Well-Controlled, Fixed-Dose Study of TEV‑50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette syndrome
TV50717-CNS-30047
Nuvelution TS Pharma
Principal Investigator
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
P2B001/003
Pharma Two B Ltd.
Principal Investigator
A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER
Revance
Sub-Investigator
A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia
RESTORE
Lundbeck
Principal Investigator
A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of dRoxidopa therapy